Presatovir

Presatovir

Presatovir

Chemical compound

Presatovir (GS-5806) is an antiviral drug which was developed as a treatment for respiratory syncytial virus.[1][2] It acts as a fusion inhibitor, and has shown promising results in Phase II clinical trials.[3][4]

Quick Facts Clinical data, Trade names ...

See also

References

  1. [1]
    Mackman RL, Sangi M, Sperandio D, Parrish JP, Eisenberg E, Perron M, et al. (February 2015). "Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study". Journal of Medicinal Chemistry. 58 (4): 1630–1643. doi:10.1021/jm5017768. PMID 25574686.
  2. [2]
    Yamaguchi-Sasaki T, Tamura Y, Ogata Y, Kawaguchi T, Kurosaka J, Sugaya Y, et al. (2020). "Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors". Chemical & Pharmaceutical Bulletin. 68 (4): 345–362. doi:10.1248/cpb.c19-00895. PMID 32238652. S2CID 214769862.
  3. [3]
    Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, et al. (December 2019). "A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract". Clinical Infectious Diseases. doi:10.1093/cid/ciz1167. PMC 7108198. PMID 31915807.
  4. [4]
    Stray K, Perron M, Porter DP, Anderson F, Lewis SA, Perry J, et al. (January 2020). "Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus". The Journal of Infectious Diseases. doi:10.1093/infdis/jiaa028. PMID 31971597.
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Presatovir, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.